Cellular evaluation of oral chemotherapy carriers

Journal of Biomedical Materials Research - Part A

Volumn 72, Issue 4, 2005, Pages 381-388

  Blanchette, James ^a   Peppas, Nicholas A ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Bleomycin; Caco 2 cells; Cancer; Hydrogel; Oral administration

Indexed keywords

CELLS; DRUG PRODUCTS; HYDROGELS; MONOLAYERS; NANOSTRUCTURED MATERIALS; POLYETHYLENE GLYCOLS; TUMORS;

BLEOMYCIN TRANSPORT; DRUG TRANSPORT; INTESTINES; METHACRYLIC ACID;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; BLEOMYCIN; DRUG CARRIER; MACROGOL DERIVATIVE; METHACRYLIC ACID DERIVATIVE; NANOPARTICLE;

ARTICLE; BLOOD FLOW; CELL LINE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SCREENING; DRUG TRANSPORT; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; INTESTINE EPITHELIUM; PH; SMALL INTESTINE; STOMACH;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLEOMYCIN; CACO-2 CELLS; DRUG CARRIERS; GASTROINTESTINAL TRACT; HUMANS; HYDROGELS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; NANOTUBES; PERMEABILITY; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS;

EID: 14644418493     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.30243     Document Type: Article

References (23)

1. Gore M, Oza A, Rustin G, Malfetano J, Calvert H, Clarke-Pearson J, et al. A randomized trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2001;38:57-63.
2. von Pawel J, Gatzmeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Cin Oncol 2001;19:1743-1749.
3. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:1009.
4. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kupermine, et al. Comparison of oral cepecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
5. Sparreboom A, de Jonge MJA, Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer 2002;38:18-22.
6. Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity, Lung Cancer 2004;43:345-353.
7. Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S, Amiden GL, et al., The challenge of proteolytic enzymes in intestinal peptide delivery. J Cont Rel 1997;46:39-57.
8. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res 1996;13:1760-1764.
9. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers D, et al. A new approach to the oral administration of insulin and other peptide drugs. Science 1986;233:1081-1084.
10. Madsen F, Peppas NA, Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials 1999;20:1701-1708.
11. Torres-Lugo M, García M, Record R, Peppas NA. Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins. J Cont Rel 2002;80:197-205.
12. Peppas NA, Klier J. Controlled release by using poly-(methacrylic acid-g-ethylene glycol) hydrogels. J Cont Rel 1991;16:203-214.
13. Lowman AM, Peppas NA. Analysis of the complexation/decomplexation phenomena in graft copolymer networks. Macromolecules 1997;30:4959-4965.
14. Lowman AM, Peppas NA. Pulsatile drug delivery based on a complexation/decomplexation mechanism. In: Dinh S, DeNuzzio J, editors. Intelligent materials and novel concepts for controlled release technologies. ACS Symp Ser. New York: ACS; 1999.
15. Blanchette J, Park K, Peppas NA. Oral administration of chemotherapeutic agents using complexation hydrogels. In: McKittrick J, Aizenberg J, Orme C, Vekilov P, editors. Biological and biomimetic materials: properties to function, Vol. 724. Pittsburgh, PA: MRS; 2002. p 215-220.
16. Delie F, Rubas W. A human colon cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 1997;14:221-286.
17. Behrens I, Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur J Pharm Sci 2003;19:433-442.
18. Weitschies W, Cordin D, Karaus M, Trahms L, Semmler W. Magnetic monitoring of the duodenal transit of capsules. Proc 2nd World Meeting APGI/APV, Paris, 25-28 May 1998; p 1145-1146.
19. Chen J, Stubbe J. Bleomycins: new methods will allow reinvestigation of old issues. Curr Opin Chem Biol 2004;8:175-181.
20. Herzog TJ. Clinical experience with topotecan in relapsed ovarian cancer, Gynecol Oncol 2003;90:S3-7.
21. Vaena DA, Walker P, Pennington K, Stephens A, Stender MJ, Ylannoutsos CT, et al. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leuk Res 2004;28:49-52.
22. De Cesare M, Zunino F, Pace S, Pisano C, Pratesi G. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer 2000;36:1558-1564.
23. Weitschies W, Kotitz R, Cordin D, Trahms L. High-resolution monitoring of the gastrointestinal transit of a magnetically marked capsule. J Pharm Sci 1997;86:1218-1222.